Jinhui Yuan
Physician Assistant · Frederick, MDNPI 1427453612
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (40.1%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Sanofi accounts for 81.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2023 at $17,929 and has fallen 90.2% since, to $1,757 in 2025. Among physician assistant clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $116.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$17K
- Novo Nordisk$1K
- Lilly USA, LLC$393
- Amgen$256
- Madrigal Pharmaceuticals$175
- Amneal Pharmaceuticals LLC$165
- plus $2K from 32 others
What the payments were for
- Consulting fees$3732%
- Speaking & faculty fees$8,40039%
- Travel & lodging$8,55040%
- Food & beverage$3,98319%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $17,393 |
| Novo Nordisk | 37 | $1,067 |
| Lilly USA, LLC | 20 | $393 |
| Amgen | 15 | $256 |
| Madrigal Pharmaceuticals | 4 | $175 |
| Amneal Pharmaceuticals LLC | 10 | $165 |
| Boehringer Ingelheim | 7 | $144 |
| Medtronic | 7 | $144 |
| Radius Health, Inc. | 5 | $117 |
| Antares Pharma, Inc. | 5 | $113 |
| Corcept Therapeutics | 6 | $110 |
| Ascendis Pharma Endocrinology Inc | 4 | $105 |
| Xeris Pharmaceuticals, Inc. | 5 | $98 |
| IBSA Pharma Inc. | 4 | $81 |
| GSK | 4 | $78 |
| Insulet Corporation | 3 | $77 |
| Dexcom, Inc. | 4 | $74 |
| BETA Bionics, Inc. | 3 | $73 |
| AbbVie | 4 | $70 |
| Sanofi-aventis U.S. LLC | 3 | $68 |
| Abbott | 4 | $65 |
| Astellas Pharma US Inc | 2 | $58 |
| Alnylam Pharmaceuticals Inc. | 3 | $53 |
| Embecta Corp. | 1 | $36 |
| Rhythm Pharmaceuticals, Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Almatica Pharma LLC | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Tactile Systems Technology Inc | 1 | $21 |
| Cequr Corporation | 1 | $20 |
| Sequel Med Tech, LLC | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Pfizer | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Biotronik NRO, Inc. | 1 | $15 |
| Nevro Corp. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,315 in reported general payments places this provider in the 95th percentile of 2,567 physician assistant providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 397 | $795,300 |
| MounjaroTirzepatide | 191 | $377,723 |
| FarxigaDapagliflozin Propanediol | 151 | $192,412 |
| JardianceEmpagliflozin | 116 | $138,897 |
| Tresiba Flextouch U-200Insulin Degludec | 100 | $133,635 |
| Tresiba Flextouch U-100Insulin Degludec | 89 | $63,657 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 45 | $52,707 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 17 | $42,160 |
| SynthroidLevothyroxine Sodium | 283 | $28,202 |
| VascepaIcosapent Ethyl | 34 | $24,248 |
| Novolog FlexpenInsulin Aspart | 65 | $23,390 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $21,742 |
| Admelog SolostarInsulin Lispro | 26 | $14,130 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 77 | $12,748 |
| Humalog Kwikpen U-100Insulin Lispro | 36 | $11,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,067 | $804,630419 claims |
| Lilly USA, LLCMounjaro | $393 | $377,723191 claims |
| AstraZenecaFarxiga | $17 | $192,412151 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $144 | $160,639137 claims |
| AmgenEvenity (2 Syringes) | $256 | $42,16017 claims |
| AbbVieSynthroid | $70 | $28,202283 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $165 | $5,453504 claims |
| Sanofi-aventis U.S. LLCAdmelog | $68 | $4,33712 claims |
| PfizerLevoxyl | $16 | $3,39086 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,567 physician assistant providers in Maryland.
Other physician assistant in Frederick
- Heather DemoryFrederick$12K
- Jessie MallalieuFrederick$10K
- Margaret JoyceTowson$220K
- Kara CossisBaltimore$177K
- Garland JamesSilver Spring$86K
- Melissa BearekmanBaltimore$81K
- Brittany YerkesSalisbury$81K
- Amy CollierTimonium$29K
- Hannah JohnsonNottingham$27K
- Lisa FoxAnnapolis$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.